Table 3.
Protocol Adherence of Radiotherapy in PMBCL Patients
| R-CHOP-21 (n = 27) |
R-CHOP-14 (n = 22) |
R-CHOP-21 + Radiotherapy (n = 43) |
R-CHOP-14 + Radiotherapy (n=39) |
|||||
|---|---|---|---|---|---|---|---|---|
| Radiotherapy yes | ||||||||
| According to protocol | - | - | 39 | (91%) | 37 | (95%) | ||
| Due to interim analysisa | 1 | (4%) | 1 | (4%) | - | - | ||
| Radiotherapy no | ||||||||
| According to the protocol | 26 | (96%) | 21 | (95%) | - | - | ||
| Insufficient response | - | - | 2 | (5%) | 1 | (3%) | ||
| Excessive toxicity | - | - | 1 | (2%) | - | |||
| Protocol violation | - | - | - | 1 | (3%)b | |||
| Patients decision | - | - | 1 | (2%) | - | |||
aAfter interim analysis, the observation arms were closed and radiotherapy was performed also in the observation arms.
bChange of treatment to autologous stem cell transplantation after 4 cycles of R-CHOP.
PMBCL = primary mediastinal B-cell lymphoma; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.